search
Back to results

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

Primary Purpose

Genital Herpes Simplex Type 2

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
GEN-003 Vaccine (30μg of each antigen)
GEN-003 Vaccine (60μg of each antigen)
Matrix-M2 Adjuvant (25μg)
Matrix-M2 Adjuvant (50μg)
Matrix-M2 Adjuvant (75μg)
Placebo
Sponsored by
Genocea Biosciences, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Genital Herpes Simplex Type 2 focused on measuring HSV, Herpes, genital infection, vaccine

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and non-pregnant females, ages 18 to 50 years inclusive.
  • Diagnosis of genital HSV-2 infection for > 1 year supported by ONE of the following documented in the medical history or performed at screening:

    • Western blot for HSV-2
    • Type-specific polymerase chain reaction (PCR) or viral culture
    • Compatible clinical history AND
  • Positive HerpeSelect® 2 Enzyme-linked Immunosorbent Assay (ELISA) Immunoglobulin G (IgG) with an index value >3.5, or
  • Positive LIAISON® HSV-2 Type-Specific IgG
  • A history of at least 3 and no more than 9 reported clinical occurrences in the prior 12 months, or, if currently on suppressive therapy, history of at least 3 and no more than 9 reported clinical occurrences in the 12 months prior to initiation of suppressive therapy.
  • Collection of at least 45 of 56 anogenital swabs during the baseline period.
  • Willing and able to provide written informed consent.
  • Willing to perform and comply with all study procedures including attending clinic visits as scheduled.
  • Men and women of childbearing potential, must be willing to practice a highly effective method of contraception that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device (IUD), or barrier method (e.g., condom, diaphragm) for 28 days before and 90 days after receiving Study Drug.

Exclusion Criteria:

  • On suppressive antiviral medication within 7 days of beginning baseline anogenital swab collection period.
  • History of genital Herpes Simplex Virus type-1 (HSV-1) infection.
  • History of any form of ocular Herpes Simplex Virus (HSV) infection, HSV-related erythema multiforme, or herpes meningitis or encephalitis.
  • Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled corticosteroids [> 960 μg/day of beclomethasone dipropionate or equivalent]) or other immunosuppressive agents.
  • Presence or history of autoimmune disease, regardless of current treatment.
  • Positive serologic test for Human Immunodeficiency Virus (HIV-1) or hepatitis C infection; positive hepatitis B surface antigen (HBsAg).
  • Clinically significant laboratory abnormality or a value ≥ Grade 2.
  • Prior immunization with a vaccine containing HSV-2 antigens.
  • History of hypersensitivity to any component of the vaccine.
  • Receipt of any investigational drug within 30 days prior to the first dose of Study Drug.
  • Receipt of blood products within 90 days prior to the first dose of Study Drug.
  • Receipt of a live vaccine within 28 days prior to or a subunit vaccine within 14 days prior to the first dose of Study Drug or planned vaccination within 30 days following the last dose of Study Drug.
  • Pregnant or nursing women.
  • History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study.
  • Other active, uncontrolled co-morbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.

NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to the first dose of Study Drug.

Sites / Locations

  • University of Alabama Vaccine Research Unit
  • Medical Center for Clinical Research
  • Quest Clinical Research
  • University of Illinois Department of Medicine
  • Indiana University Infectious Disease Research
  • The Fenway Institute
  • UNC Global HIV Prevention and Treatment Clinical Trials Unit
  • Cincinnati Children's Hospital Medical Center
  • Westover Heights Clinic
  • Magee-Womens Hospital of UPMC
  • Tekton Research
  • Center for Clinical Studies - Houston
  • Center for Clinical Studies
  • Center for Clinical Studies - Clear Lake/Webster
  • University of Utah
  • UW Virology Research Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

GEN-003 Vaccine 30μg / Matrix-M 25μg

GEN-003 Vaccine 30μg / Matrix-M2 50μg

GEN-003 Vaccine 30μg / Matrix-M2 75μg

GEN-003 Vaccine 60μg / Matrix-M2 25μg

GEN-003 Vaccine 60μg / Matrix-M2 50μg

GEN-003 Vaccine 60μg / Matrix-M2 75μg

Placebo

Arm Description

GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.

GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.

GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.

GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.

GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.

GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.

0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.

Outcomes

Primary Outcome Measures

Change in proportion of days with detectable viral shedding

Secondary Outcome Measures

Immunogenicity measured by humoral (antibody) and T-cell responses to vaccine antigens
Impact on clinical HSV-2 disease based on time to recurrence and lesion rate
Number of patients with adverse events as a measure of safety and tolerability

Full Information

First Posted
April 11, 2014
Last Updated
October 6, 2017
Sponsor
Genocea Biosciences, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02114060
Brief Title
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
Official Title
A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Genocea Biosciences, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized, double-blind, factorial study to compare the reduction in viral shedding among 6 different combinations of GEN-003, a therapeutic HSV-2 vaccine and Matrix-M2 adjuvant. Secondary objectives of the study include: Evaluation of the safety and tolerability of GEN-003 in combination with Matrix-M2 compared to placebo. Comparison of the impact on clinical Herpes Simplex Virus type-2 (HSV-2) disease among the 6 different combinations of GEN-003 antigens and Matrix-M2 adjuvant measured by: Time to first clinical and/or virologic recurrence, Proportion of subjects who are recurrence free at 6 and 12 months after the last dose of vaccine, Lesion rate (percent of days with genital lesions present) during the post-vaccination swabbing periods. Evaluation of cellular and humoral responses to GEN-003 antigens. Additional objectives include: Assessment of the correlation between immune responses and change in viral shedding or impact on clinical disease as defined above. Determination of the recurrence rate in a subset of subjects not receiving suppressive antivirals throughout the study. Eligible subjects will enter a baseline period to collect anogenital swabs for 28 consecutive days prior to randomization. Each subject will receive up to 3 doses at 21 day intervals. Subjects will be followed for safety and immunologic response for 12 months following their last dose.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genital Herpes Simplex Type 2
Keywords
HSV, Herpes, genital infection, vaccine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
310 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GEN-003 Vaccine 30μg / Matrix-M 25μg
Arm Type
Experimental
Arm Description
GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
Arm Title
GEN-003 Vaccine 30μg / Matrix-M2 50μg
Arm Type
Experimental
Arm Description
GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
Arm Title
GEN-003 Vaccine 30μg / Matrix-M2 75μg
Arm Type
Experimental
Arm Description
GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
Arm Title
GEN-003 Vaccine 60μg / Matrix-M2 25μg
Arm Type
Experimental
Arm Description
GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
Arm Title
GEN-003 Vaccine 60μg / Matrix-M2 50μg
Arm Type
Experimental
Arm Description
GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
Arm Title
GEN-003 Vaccine 60μg / Matrix-M2 75μg
Arm Type
Experimental
Arm Description
GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
Intervention Type
Biological
Intervention Name(s)
GEN-003 Vaccine (30μg of each antigen)
Other Intervention Name(s)
HSV Vaccine
Intervention Description
HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
Intervention Type
Biological
Intervention Name(s)
GEN-003 Vaccine (60μg of each antigen)
Other Intervention Name(s)
HSV Vaccine
Intervention Description
HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
Intervention Type
Biological
Intervention Name(s)
Matrix-M2 Adjuvant (25μg)
Other Intervention Name(s)
MM2, Adjuvant
Intervention Description
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Intervention Type
Biological
Intervention Name(s)
Matrix-M2 Adjuvant (50μg)
Other Intervention Name(s)
MM2, Adjuvant
Intervention Description
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Intervention Type
Biological
Intervention Name(s)
Matrix-M2 Adjuvant (75μg)
Other Intervention Name(s)
MM2, Adjuvant
Intervention Description
Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
Intervention Type
Biological
Intervention Name(s)
Placebo
Other Intervention Name(s)
0.9% Normal Saline (NaCl)
Intervention Description
0.9% Normal Saline (NaCl)
Primary Outcome Measure Information:
Title
Change in proportion of days with detectable viral shedding
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Immunogenicity measured by humoral (antibody) and T-cell responses to vaccine antigens
Time Frame
33 weeks
Title
Impact on clinical HSV-2 disease based on time to recurrence and lesion rate
Time Frame
53 weeks
Title
Number of patients with adverse events as a measure of safety and tolerability
Time Frame
57 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and non-pregnant females, ages 18 to 50 years inclusive. Diagnosis of genital HSV-2 infection for > 1 year supported by ONE of the following documented in the medical history or performed at screening: Western blot for HSV-2 Type-specific polymerase chain reaction (PCR) or viral culture Compatible clinical history AND Positive HerpeSelect® 2 Enzyme-linked Immunosorbent Assay (ELISA) Immunoglobulin G (IgG) with an index value >3.5, or Positive LIAISON® HSV-2 Type-Specific IgG A history of at least 3 and no more than 9 reported clinical occurrences in the prior 12 months, or, if currently on suppressive therapy, history of at least 3 and no more than 9 reported clinical occurrences in the 12 months prior to initiation of suppressive therapy. Collection of at least 45 of 56 anogenital swabs during the baseline period. Willing and able to provide written informed consent. Willing to perform and comply with all study procedures including attending clinic visits as scheduled. Men and women of childbearing potential, must be willing to practice a highly effective method of contraception that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device (IUD), or barrier method (e.g., condom, diaphragm) for 28 days before and 90 days after receiving Study Drug. Exclusion Criteria: On suppressive antiviral medication within 7 days of beginning baseline anogenital swab collection period. History of genital Herpes Simplex Virus type-1 (HSV-1) infection. History of any form of ocular Herpes Simplex Virus (HSV) infection, HSV-related erythema multiforme, or herpes meningitis or encephalitis. Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months prior to the first dose of Study Drug, any dose of corticosteroids within 30 days of the first dose of Study Drug, or high dose inhaled corticosteroids [> 960 μg/day of beclomethasone dipropionate or equivalent]) or other immunosuppressive agents. Presence or history of autoimmune disease, regardless of current treatment. Positive serologic test for Human Immunodeficiency Virus (HIV-1) or hepatitis C infection; positive hepatitis B surface antigen (HBsAg). Clinically significant laboratory abnormality or a value ≥ Grade 2. Prior immunization with a vaccine containing HSV-2 antigens. History of hypersensitivity to any component of the vaccine. Receipt of any investigational drug within 30 days prior to the first dose of Study Drug. Receipt of blood products within 90 days prior to the first dose of Study Drug. Receipt of a live vaccine within 28 days prior to or a subunit vaccine within 14 days prior to the first dose of Study Drug or planned vaccination within 30 days following the last dose of Study Drug. Pregnant or nursing women. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study. Other active, uncontrolled co-morbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements. NOTE: Subjects who are taking a medication to control an underlying co-morbidity may be enrolled if there have been no changes to their medication within 60 days prior to the first dose of Study Drug.
Facility Information:
Facility Name
University of Alabama Vaccine Research Unit
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-0006
Country
United States
Facility Name
Medical Center for Clinical Research
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
Facility Name
Quest Clinical Research
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
Facility Name
University of Illinois Department of Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Indiana University Infectious Disease Research
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
The Fenway Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
UNC Global HIV Prevention and Treatment Clinical Trials Unit
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229-3039
Country
United States
Facility Name
Westover Heights Clinic
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Facility Name
Magee-Womens Hospital of UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Tekton Research
City
Austin
State/Province
Texas
ZIP/Postal Code
98745
Country
United States
Facility Name
Center for Clinical Studies - Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Center for Clinical Studies
City
Houston
State/Province
Texas
ZIP/Postal Code
77065
Country
United States
Facility Name
Center for Clinical Studies - Clear Lake/Webster
City
Webster
State/Province
Texas
ZIP/Postal Code
77598
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
Facility Name
UW Virology Research Clinic
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

We'll reach out to this number within 24 hrs